Table 1

Comparison of baseline variables between patients with or without registered dispensations of antibiotics in the year prior to anti-TNF initiation

VariableTotal (n=1946)With prior antibiotics (n=1593)No prior antibiotics (n=353)P value
Age, years29 (24)29 (24)27 (23)0.59
Male, n (%)1035 (53)826 (52)211 (60)0.01
BMI*, kg/m²22 (6.2)22 (6)22 (6)0.53
Adalimumab, n (%)1065 (55)868 (54)197 (56)0.7
Prior anti-TNF, n (%)567 (29)493 (31)74 (21)<0.001
Crohn’s, n (%)1595 (82)1307 (82)288 (82)0.9
Prior related surgery526 (27)437 (27)89 (25)0.43
Recent prior hospitalisations886 (46)558 (46)328 (45)0.06
Laboratory results, median (IQR)
 Haemoglobin*, g/dL12.8 (2.2)12.7 (2.2)13 (2.2)0.07
 WBC*,×109/L7.3 (3.1)7.3 (3.1)7 (3.1)0.08
 Platelets*, ×109/L284 (119)285 (121)282 (105)0.3
 CRP*, mg/dL0.9 (2)0.9 (2.1)0.8 (1.7)0.14
 Albumin*, g/dL4.1 (0.6)4.1 (0.5)4.1 (0.5)0.13
Prior/concomitant medications, n (%)
 Corticosteroids236 (12)197 (12)39 (11)0.55
 Thiopurines856 (44)713 (45)134 (41)0.16
 Methotrexate133 (7)116 (7)17 (5)0.12
 5-ASA572 (29)481 (30)91 (26)0.11
Time (days) to antibody monitoring
 Time to first measure, days675 (1136)611 (1249)406 (923)<0.001
 Time to end of follow-up, days651 (1175)703 (1227)475 (929)<0.001
  • *Data for these variables were not available for all included patients. Availability of each variable was as follows: BMI, 93%; haemoglobin, 98.9%; WBC, 98.9%; platelets, 98.9%; CRP, 80.3%; albumin, 94.3%.

  • anti-TNF, anti-tumour necrosis factor ; 5-ASA, 5-aminosalicylic acid; BMI, body mass index; CRP, C reactive protein; ; WBC, white blood cells.